CA
IMCR icon

Continuum Advisory’s Immunocore IMCR Stock Holding History

Continuum Advisory’s Portfolio IMCR Stock Details IMCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-47
Closed -$1.39K – 971
2025
Q1 		$1.39K Hold
47
– – ﹤0.01% 1447
2024
Q4 		$1.39K Sell
47
-20
-30% -$632 ﹤0.01% 1540
2024
Q3 		$2.19K Buy
67
+40
+148% +$1.46K ﹤0.01% 1398
2024
Q2 		$915 Hold
27
– – ﹤0.01% 1493
2024
Q1 		$1.62K Buy
+27
New +$1.85K ﹤0.01% 1355

Other funds holding IMCR

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Continuum Advisory's IMCR Position: Q2 2025 in Review

Continuum Advisory sold out of Immunocore (IMCR) in Q2 2025, closing a stake of 47 shares — an estimated $1.39K sold.

Continuum Advisory first reported a position in IMCR in Q1 2024 and held it in 5 quarters. The position peaked at $2.19K in Q3 2024. 133 funds tracked by Wall St. Rank hold IMCR as of Q2 2025.

  • Continuum Advisory reported no remaining Immunocore position as of Q2 2025 after selling out during the quarter.
  • Continuum Advisory sold 47 Immunocore shares in Q2 2025, an estimated $1.39K.
  • Continuum Advisory first reported a position in Immunocore in Q1 2024 and held it in 5 quarters.
  • Continuum Advisory's Immunocore position peaked at $2.19K in Q3 2024.
  • 133 funds tracked by Wall St. Rank held Immunocore as of Q2 2025.

Based on Continuum Advisory's 13F filing for Q2 2025, filed 13 Aug 2025.